Review
doi: 10.1177/095632020201300601.
The quest for an efficacious antiviral for respiratory syncytial virus
Affiliations
- PMID: 12718405
- DOI: 10.1177/095632020201300601
Item in Clipboard
Review
The quest for an efficacious antiviral for respiratory syncytial virus
Antivir Chem Chemother.
2002 Nov.
Free article
Abstract
Respiratory syncytial virus (RSV) continues as an emerging infectious disease not only among infants and children, but also for the immune-suppressed, hospitalized and the elderly. To date, ribavirin (Virazole) remains the only therapeutic agent approved for the treatment of RSV. The prophylactic administration of palivizumab is problematic and costly. The quest for an efficacious RSV antiviral has produced a greater understanding of the viral fusion process, a new hypothesis for the mechanism of action of ribavirin, and a promising antisense strategy combining the 2'-5' oligoadenylate antisense (2-5A-antisense) approach and RSV genomics.
Similar articles
-
2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection.Curr Opin Mol Ther. 1999 Jun;1(3):307-15. Curr Opin Mol Ther. 1999. PMID: 11713795 Review.
-
Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense.Virology. 2002 Jan 5;292(1):70-7. doi: 10.1006/viro.2001.1213. Virology. 2002. PMID: 11878909
-
Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin.Antiviral Res. 2004 Mar;61(3):195-206. doi: 10.1016/j.antiviral.2003.10.005. Antiviral Res. 2004. PMID: 15168801
-
New strategies for control of respiratory syncytial virus infection.Curr Opin Infect Dis. 2008 Dec;21(6):639-43. doi: 10.1097/QCO.0b013e3283184245. Curr Opin Infect Dis. 2008. PMID: 18978532 Review.
-
Recruiting the 2-5A system for antisense therapeutics.Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):203-6. doi: 10.1089/oli.1.1997.7.203. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9212911 Review. No abstract available.
Cited by
-
Respiratory Viral Infections and Subversion of Cellular Antioxidant Defenses.J Pharmacogenomics Pharmacoproteomics. 2014 Sep 30;5(4):1000141. doi: 10.4172/2153-0645.1000141. J Pharmacogenomics Pharmacoproteomics. 2014. PMID: 25584194 Free PMC article.
-
Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice.Mol Ther. 2008 Jun;16(6):1120-8. doi: 10.1038/mt.2008.81. Epub 2008 Apr 29. Mol Ther. 2008. PMID: 18443602 Free PMC article.
-
Respiratory syncytial virus infection: mechanisms of redox control and novel therapeutic opportunities.Antioxid Redox Signal. 2013 Jan 10;18(2):186-217. doi: 10.1089/ars.2011.4307. Epub 2012 Sep 7. Antioxid Redox Signal. 2013. PMID: 22799599 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
